Table 2.

Demographic and clinical data

Data	Number	Meana	95 % observation interval	Change in TDM Group after transplantation				Number of missing data points
				Day 1		Day 70
				Mean	95 % observation interval	Mean	95 % observation interval
Demographic data
Patients	69
Sex (male /female)	50/19							0/69
CYP3A5 genotype (*1/*1, *1/*3, *3/*3)	0/10/59							0/69
Age (years)		43	22–73					0/69
Height (cm)		176	151–197					0/69
Total body weight (kg)		81	51–131	83	53–140	80	49–128	142/1,546
Predicted fat-free mass (kg)		59	40–82	60	41–84	55	39–82	142/1,546
Hematocrit (%)		36	29–43	31	25–39	38	32–42	109/1,546
Serum creatinine (μmol/L)		147	73–347	409	123–1,079	120	78–208	2/1,546
C-reactive protein (mg/L)		7	<0.6–24	12	<0.6–34	3	<0.6–10	49/1,546
Serum albumin (g/L)		42	33–47	37	27–45	45	37–50	498/1,546
Total serum bilirubin (μmol/L)		7	3–13	5	1–14	6	3–15	500/1,546
Aspartate aminotransferase (IU/L)		23	15–40	35	13–111	20	14–29	498/1,546
Alanine aminotransferase (IU/L)		31	10–91	50	13–170	22	11–43	498/1,546
Alkaline phosphatase (IU/L)		66	30–106	60	34–95	70	41–105	499/1,546
Pharmacokinetic data (TDM Group)
Samples	1,032
Samples per patient		23	13–29
Tacrolimus trough concentration (μg/L)		7.0	2.7–12.4
Pharmacokinetic data (Intensive Group)
Samples	514
Samples per patient		18	9–39
Tacrolimus concentration (μg/L)		11.3	3.4–26.7

CYP3A5, Cytochrome P450 3A5; TDM, therapeutic drug monitoring

^aCalculated from mean value across all observation times in each patient